Comparing in-person and remote monitoring for cancer follow-up
Official title: Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
Run by Centre Oscar Lambret · NCT05500391 · Data updated 2026-11-12
This study is testing whether patients with rare tumors follow their post-treatment care plans better with in-person visits from a doctor or remote check-ins with a nurse.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 88 (estimated) |
| Sponsor | Centre Oscar Lambret Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Amiens and 2 other locations) |
| Status | Recruiting |
| Started | February 28, 2024 |
| Main results expected | October 2026 |
| Study ends | July 2032 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT05500391 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have been diagnosed with specific rare tumors within the last 12 months.
✕Probably not a fit
Patients who are unable to undergo the required imaging tests or do not have access to telemedicine may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, interventional study aims to evaluate compliance with personalized post-treatment surveillance plans for patients diagnosed with rare tumors within the last 12 months. Participants will be randomly assigned to receive follow-up care either in person by a physician or remotely by a trained nurse. The primary objective is to compare 2-year compliance rates between the two groups, while secondary objectives include long-term compliance, care utilization, and management of oncological events. Exploratory objectives will assess costs, patient satisfaction, psychological well-being, and reasons for recruitment failures.
Why it matters
Potential benefit: If successful, this study could enhance patient compliance with follow-up care, potentially improving outcomes for those with rare tumors.
How similar studies have gone: Other studies have shown promise in remote monitoring approaches, but this specific comparison of in-person versus remote follow-up in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Positive diagnosis (anatomopathology) of tumor within 12 months * Patient 18 years of age or older * Patient with one of the following conditions: 1. Desmoid fibromatosis of the abdominal wall operated on or under active surveillance 2. Stage I testicular seminoma (whether or not treated with carboplatin AUC7) 3. Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy) 4. Operated GIST with low risk of relapse 5. Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated 6. Low-grade glioma, operated 7. Low-grade neuroendocrine tumor, treated by surgery alone * Patient who has given consent to participate in the study Exclusion Criteria: * Contraindication to imaging tests required for the surveillance plan * No telephone * Patient under guardianship or curatorship
Where it's running
-
Centre Oscar Lambret
Lille, France Recruiting -
CHU Amiens
Amiens, France Not yet recruiting -
Centre François Baclesse
Caen, France Not yet recruiting
Study contacts
- Principal investigator: PENEL Nicolas, MD, PhD — Centre Oscar Lambret
- Study coordinator: Laurence ROTSAERT
- Email: l-rotsaert@o-lambret.fr
- Phone: 0320295860 / 0320295918
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dual-nuclide PET/CT imaging to test simultaneous tracer separation in cancer patients and healthy volunteers
This study tests a simultaneous dual-tracer PET/CT imaging method in prostate cancer, neuroendocrine tumors, glioma, lung cancer patients, and healthy volunteers to see if it can accurately separate and measure two tracers in humans.
-
Testing a new drug for advanced solid tumors that express c-Kit
This study is testing a new drug for people with advanced solid tumors that have a specific marker called c-Kit to see if it is safe and how well it works.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.